Study Evaluating SKI-606 Administered to Healthy Subjects

This study has been completed.
Sponsor:
Information provided by:
Wyeth is now a wholly owned subsidiary of Pfizer
ClinicalTrials.gov Identifier:
NCT00406406
First received: November 29, 2006
Last updated: December 3, 2007
Last verified: December 2007
  Purpose

Safety and tolerability of SKI-606 in healthy subjects; the influence of food intake on the same.


Condition Intervention Phase
Healthy
Drug: SKI-606
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SKI-606 Administered Orally to Healthy Subjects

Resource links provided by NLM:


Further study details as provided by Wyeth is now a wholly owned subsidiary of Pfizer:

Primary Outcome Measures:
  • Pharmacokinetics; safety and tolerability; influence of food.

Study Start Date: November 2006
Study Completion Date: August 2007
  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00406406

Locations
Netherlands
Utrecht, Netherlands, 3584 CJ
Sponsors and Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
Investigators
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
Principal Investigator: Trial Manager For Netherlands, trials-NL@wyeth.com
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00406406     History of Changes
Other Study ID Numbers: 3160A1-103
Study First Received: November 29, 2006
Last Updated: December 3, 2007
Health Authority: Netherlands: Medical Ethics Review Committee (METC)

ClinicalTrials.gov processed this record on April 16, 2014